Article Information
History
- November 5, 2020.
Copyright
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Emma C. Thomson1,2,*,
- Laura E. Rosen3,*,
- James G. Shepherd1,*,
- Roberto Spreafico3,*,
- Ana da Silva Filipe1,
- Jason A. Wojcechowskyj3,
- Chris Davis1,
- Luca Piccoli4,
- David J. Pascall5,
- Josh Dillen3,
- Spyros Lytras1,
- Nadine Czudnochowski3,
- Rajiv Shah1,
- Marcel Meury3,
- Natasha Jesudason1,
- Anna De Marco4,
- Kathy Li1,
- Jessica Bassi4,
- Aine O’Toole6,
- Dora Pinto4,
- Rachel M. Colquhoun6,
- Katja Culap4,
- Ben Jackson6,
- Fabrizia Zatta4,
- Andrew Rambaut6,
- Stefano Jaconi4,
- Vattipally B. Sreenu1,
- Jay Nix7,
- Ruth F. Jarrett1,
- Martina Beltramello4,
- Kyriaki Nomikou1,
- Matteo Pizzuto4,
- Lily Tong1,
- Elisabetta Cameroni4,
- Natasha Johnson1,
- Arthur Wickenhagen1,
- Alessandro Ceschi8,9,10,
- Daniel Mair1,
- Paolo Ferrari11,12,
- Katherine Smollett1,
- Federica Sallusto13,
- Stephen Carmichael1,
- Christian Garzoni14,
- Jenna Nichols1,
- Massimo Galli15,
- Joseph Hughes1,
- Agostino Riva15,
- Antonia Ho1,
- Malcolm G. Semple16,17,
- Peter J.M. Openshaw18,
- J. Kenneth Baillie19,20,
- The ISARIC4C Investigators21,
- the COVID-19 Genomics UK (COG-UK) consortium22,
- Suzannah J. Rihn1,
- Samantha J. Lycett19,
- Herbert W. Virgin3,23,
- Amalio Telenti3,
- Davide Corti4,
- David L. Robertson1 and
- Gyorgy Snell3,†
- 1MRC-University of Glasgow Centre for Virus Research, University of Glasgow, Glasgow, G61 1QH, UK
- 2Department of Clinical Research, London School of Hygiene and Tropical Medicine, Keppel Street, London, WC1E 7HT, UK
- 3Vir Biotechnology, San Francisco, California 94158, USA
- 4Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland
- 5Institute of Biodiversity, Animal Health and Comparative Medicine, Boyd Orr Centre for Population and Ecosystem Health, University of Glasgow, Glasgow, G61 1QH, UK
- 6Institute of Evolutionary Biology, University of Edinburgh, Edinburgh, UK
- 7Molecular Biology Consortium, Advanced Light Source, Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
- 8Faculty of Biomedical Sciences, Università della Svizzera italiana, Lugano, Switzerland
- 9Division of Clinical Pharmacology and Toxicology, Institute of Pharmacological Sciences of Southern Switzerland, Ente Ospedaliero Cantonale, Lugano, Switzerland
- 10Department of Clinical Pharmacology and Toxicology, University Hospital Zurich, Zurich, Switzerland
- 11Department of Nephrology, Ospedale Civico Lugano, Ente Ospedaliero Cantonale, Lugano, Switzerland
- 12Prince of Wales Hospital Clinical School, University of New South Wales, Sydney, Australia
- 13Institute for Research in Biomedicine, Università della Svizzera italiana, Bellinzona, Switzerland
- 14Clinic of Internal Medicine and Infectious Diseases, Clinica Luganese Moncucco, 6900 Lugano, Switzerland
- 15III Division of Infectious Diseases, ASST Fatebenefratelli Sacco, Luigi Sacco Hospital, 20157 Milan, Italy
- 16NIHR Health Protection Research Unit, Institute of Infection, Veterinary and Ecological Sciences, Faculty of Health and Life Sciences, University of Liverpool, Liverpool, UK
- 17Respiratory Medicine, Alder Hey Children’s Hospital, Institute in The Park, University of Liverpool, Alder Hey Children’s Hospital, Liverpool L12 2AP, UK
- 18National Heart and Lung Institute, Imperial College London, London, UK
- 19The Roslin Institute, University of Edinburgh, EH25 9RG Edinburgh, UK
- 20Intensive Care Unit, Royal Infirmary Edinburgh, Edinburgh, UK
- 23Washington University School of Medicine, Saint Louis, Missouri 63110, USA
- ↵†Correspondence: gsnell{at}vir.bio, david.l.robertson{at}glasgow.ac.uk
↵* These authors contributed equally
Posted November 05, 2020.
The circulating SARS-CoV-2 spike variant N439K maintains fitness while evading antibody-mediated immunity
